Intelligent Investor
Intelligent Investor
  1. Home
  2. Research & Advice
  3. Research Tools
  4. Shares
  5. Telix Pharmaceuticals Limited (BDX)
Sign up for free Sign up for free Sign up for free

BCAL Diagnostics Limited (ASX: BDX) - Share Price and Research

Current share price for BDX : $0.075 0.001 (1.32%)+

BCAL Diagnostics Limited (BDX), an ASX-listed company, is an Australian company focused on development of a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost effective, accurate and available to all women regardless of age, race and geographic location.

BDX General Information +

ASX Code BDX
Website http://www.bcaldiagnostics.com
Industry/Sector Biotechnology
Market Cap ($M) 27
BDX Share Price $0.075
Day High $0.078
Day Low $0.075
Last Close $0.076
BDX Share Price Movement $0.00 ( 1.32% )
Prices as at 16:40, 30 May 2025
+Security prices are delayed by at least 20 minutes and are indicative only.
Trial Banner Trial Banner Trial Banner

BDX Share Price Chart - AUD ($)

Upsell Banner

BDX Related Research

BCAL Diagnostics Limited (BDX) Upcoming Dividends & Yields

There are no dividends for BCAL Diagnostics Limited (BDX). Please use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

BCAL Diagnostics Limited (BDX) price-sensitive announcements

BDX - Quarterly Activities/Appendix 4C Cash Flow Report
BCAL Diagnostics Limited has successfully launched its innovative non-invasive breast canc
BCAL Diagnostics Limited (BDX)
28 Apr 2025 | 12:13 PM
BDX - Investor Presentation
BCAL Diagnostics Limited is advancing breast cancer screening through a non-invasive blood
BCAL Diagnostics Limited (BDX)
24 Mar 2025 | 10:46 AM
BDX - BCAL Launches Breastest Plus Generating First Revenues
BCAL Diagnostics Limited has officially launched its innovative breast cancer diagnostic t
BCAL Diagnostics Limited (BDX)
24 Mar 2025 | 9:47 AM
BDX - Half Yearly Report and Accounts
The BCAL Diagnostics Limited half-year report for the period ending December 31, 2024, hig
BCAL Diagnostics Limited (BDX)
28 Feb 2025 | 9:06 AM

See more price-sensitive ASX announcements or use our ASX Announcements tool to search for announcements across all ASX-listed securities.

BCAL Diagnostics Limited (BDX) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
BCAL Diagnostics Limited (BDX)
ORDINARY FULLY PAID
 Health Care $27 BCAL Expands Access to Breastest Plus Sydney & Melbourne 6 May 2025 9:36AM $0.078 $0.075 fallen by 3.85%
BCAL Diagnostics Limited (BDX)
ORDINARY FULLY PAID
 Health Care $27 Quarterly Activities/Appendix 4C Cash Flow Report 28 Apr 2025 12:13PM $0.084 $0.075 fallen by 10.71%
BCAL Diagnostics Limited (BDX)
ORDINARY FULLY PAID
 Health Care $27 BCAL to Host Analyst and Investor Webinar on 2 April 2025 31 Mar 2025 8:19AM $0.105 $0.075 fallen by 28.57%
BCAL Diagnostics Limited (BDX)
ORDINARY FULLY PAID
 Health Care $27 Investor Presentation 24 Mar 2025 10:46AM $0.105 $0.075 fallen by 28.57%
BCAL Diagnostics Limited (BDX)
ORDINARY FULLY PAID
 Health Care $27 BCAL Launches Breastest Plus Generating First Revenues 24 Mar 2025 9:47AM $0.098 $0.075 fallen by 23.47%
BCAL Diagnostics Limited (BDX)
ORDINARY FULLY PAID
 Health Care $27 Half Yearly Report and Accounts 28 Feb 2025 9:06AM $0.110 $0.075 fallen by 31.82%

BDX Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2024A -$6.40 -$2.60 8.30% 0.00 0.00 0.00% 0.0%
2023A -$5.06 -$2.40 44.60% 0.00 0.00 0.00% 0.0%
2022A -$3.39 -$1.70 0.00% 0.00 0.00 0.00% 0.0%

BDX Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2022 A 2023 A 2024 A 2022 A 2023 A 2024 A 2022 A 2023 A 2024 A
BCAL Diagnostics Limited (BDX) $28M 0.0833 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
CSL Limited (CSL) $120,085M 0.2288 -0.2266 0.1179 29.5386 38.1920 34.1654 1.61% 1.18% 1.30%
Mesoblast Limited (MSB) $2,128M -0.3176 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Opthea Limited (OPT) $739M 0.2355 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Telix Pharmaceuticals Limited (TLX) $8,612M 9.9840 1.1090 0.5883 123.3414 58.4845 36.8223 0.00% 0.00% 0.00%

BDX Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 2.75 0.00
Market 0.23 13.50 1.08 0.93
Sector 1.01 19.80 2.05 1.04

BDX Directors

Name Position Start Date
Ms Jayne Andrea Shaw Executive Chairman, Executive Director 15 Feb 2010
Mr Mark Douglas Irving Burrows Non-Executive Director 21 Jul 2021
Mr David George Darling Non-Executive Director 1 Mar 2024
Dr John Hurrell Non-Executive Director 2 Apr 2024
Mr Jonathan Alfred Grey Trollip Non-Executive Director 23 Dec 2020
Hon Ronald (Ron) Anthony Phillips Non-Executive Director 15 Feb 2010

BCAL Diagnostics Limited (BDX) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
6 Nov 2024 SHAW, Jayne Buy Indirect Shares 480,748 $0.105 $50,478.000
13 Sep 2024 SHAW, Jayne Buy Indirect Shares 125,000 $0.115 $14,375.000
4 Sep 2024 DARLING, David Buy Direct Shares 35,880 $0.125 $4,485.000

See all changes in directors' interest & trades for BCAL Diagnostics Limited (BDX) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

BDX Management

Name Position
Shane Ryan Chief Executive Officer
Guy Adrian Robertson Chief Financial Officer,Company Secretary
Amani Batarseh Chief Scientific Officer

BDX Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Telix Pharmaceuticals Limited (BDX). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
33,293,425 (9.31%) Capital Property Corporation Pty Ltd
31,914,418 (8.92%) Jayne Andrea Shaw
28,937,205 (8.09%) Ronald Anthony Phillips
22,093,215 (6.17%) Mera Vale No 1 Pty Ltd

BDX Calendar of Events

Date Event
27 February 2026 Report (Interim)
29 August 2025 Report (Annual)
29 August 2025 Report (Prelim)

FAQs about Telix Pharmaceuticals Limited (BDX)

Telix Pharmaceuticals Limited's (BDX) current share price is $0.08. This constitutes a price movement of 1.32% when compared to the share price 7 days ago and is -54.55% below BDX's 12-month high of $0.17 per share. Prices are delayed by at least 20 minutes.

Relative to the previous close share price of $0.08, Telix Pharmaceuticals Limited's (BDX) current share price of $0.08 constitutes a movement of $0.00 or -1.32%. Telix Pharmaceuticals Limited's (BDX) share price movement is -1.32% when compared to 7 days ago and is -54.55% below BDX's 52-week high of $0.17.

Telix Pharmaceuticals Limited's (BDX) 52-week high is $0.17 which was reached on 12 Jul 2024. Relative to this, BDX's current share price of $0.08 constitutes a -$0.09 or -54.55% drop since that high of $0.17 per BDX share.

Telix Pharmaceuticals Limited's (BDX) 52-week low is $0.08 which was reached on 8 May 2025. Relative to this, BDX's current share price of $0.08 constitutes a or 0% drop since that low of $0.08 per BDX share.

Over the last 12 months, Telix Pharmaceuticals Limited (BDX) has a daily average trading volume of 398,936 BDX shares per day.

Telix Pharmaceuticals Limited (BDX) has a current dividend yield of n/a this year. Last year's dividend yield was 0%. The dividend yield for BDX is a ratio that tells you the percentage of Telix Pharmaceuticals Limited's (BDX) share price that it pays out in dividends each year.

Telix Pharmaceuticals Limited (BDX) will release its next Annual Report on 29 August 2025. Telix Pharmaceuticals Limited's (BDX) last annual report was released on 30 Aug 2024. Click here to view Telix Pharmaceuticals Limited's (BDX) last annual report.

Telix Pharmaceuticals Limited (BDX) is classified as Health Care. Other companies in this sector include CSL Limited (CSL), Sigma Healthcare Limited (SIG), Pro Medicus Limited (PME), and ResMed Inc. (RMD).

The price-to-earnings (P/E) ratio for Telix Pharmaceuticals Limited (BDX) is 0. The price-to-earnings ratio, also known as P/E ratio, P/E, or PER, is the ratio of Telix Pharmaceuticals Limited's (BDX) share price to its earnings per BDX share.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.